Alnylam Pharmaceuticals, Inc. vs CRISPR Therapeutics AG: SG&A Expense Trends

SG&A Expense Trends: Alnylam Pharmaceuticals vs. CRISPR Therapeutics

In the rapidly evolving biotech industry, understanding financial trends is crucial. This analysis focuses on the Selling, General, and Administrative (SG&A) expenses of Alnylam Pharmaceuticals, Inc. and CRISPR Therapeutics AG from 2014 to 2023.

Alnylam Pharmaceuticals, a leader in RNA interference therapeutics, has seen its SG&A expenses grow significantly, increasing by over 1,600% from 2014 to 2023. This reflects their aggressive expansion and investment in commercial infrastructure. In contrast, CRISPR Therapeutics, a pioneer in gene-editing technology, experienced a more modest increase of approximately 1,400% in the same period.

By 2023, Alnylam's SG&A expenses were nearly 10 times higher than CRISPR's, highlighting their different strategic focuses. While Alnylam invests heavily in market penetration, CRISPR appears to prioritize research and development. This divergence in financial strategy underscores the varied approaches within the biotech sector, offering insights into each company's growth trajectory and market positioning.